Supernus, Inc. SUPN
SUPN is a Supernus, Inc. note, preferred share or other security listed on Nasdaq. Its price is shown below; holders, insider trades and filings are for the company. The company’s common stock is INDV →
Latest 10-Q
What changed in Supernus, Inc.'s latest quarterly report, compared with the one before.
Loading…
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Trades by members of Congress
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Executive-branch trades
6 tradesTrades in Supernus, Inc. reported by the President, Cabinet members and other senior executive-branch officials. Amounts are ranges.Form 278-T is the periodic transaction report that senior executive-branch officials file with the Office of Government Ethics. They must report each trade over $1,000 within 30 days of being notified of it, and no later than 45 days after the trade. Amounts are ranges, not exact figures.
| The form has no ticker column. The asset is shown as the filer wrote it. We add a ticker link only when we could match the asset to a listed company. | The form asks for a range, such as $1,001 - $15,000, not an exact amount. A line can be left blank when the filer's note says the amount was not more than $1,000. | Report | ||||
|---|---|---|---|---|---|---|
| Donald J Trump President of the United States | INDIVIOR PHARMACEUTICALS read from scan | Sale | Jul 29, 2026 | $15,001 - $50,000 | Sep 8, 2026 | White House report ↗ |
| Donald J Trump President of the United States | INDIVIOR PHARMACEUTICALS read from scan | Purchase | Jun 4, 2026 | $15,001 - $50,000 | Aug 12, 2026 | White House report ↗ |
| Donald J Trump President of the United States | INDIVIOR PHARMACEUTICALS read from scan | Sale | May 15, 2026 | $50,001 - $100,000 | Jun 25, 2026 | White House report ↗ |
| Donald J Trump President of the United States | INDIVIOR PHARMACEUTICALS read from scan | Purchase | Mar 30, 2026 | $50,001 - $100,000 | May 8, 2026 | White House report ↗ |
| Donald J Trump President of the United States | INDIVIOR PHARMACEUTICALS read from scan | Sale | Feb 26, 2026 | $50,001 - $100,000 | May 8, 2026 | White House report ↗ |
Lobbying
What Supernus, Inc. and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Loading…
More filings and data
Each opens the table.
About the company
The basics from the company’s SEC registration.
Loading…
Price of SUPN, not of the company’s common stock
Adjusted for stock splits; not for dividends. Where prices come from.
Live chart
Intraday and historical prices from TradingView. Quotes may be delayed.
Information, not investment advice. Company matching is automatic; check the source before relying on one row.